Hydroxychloroquine (HCQS), with versions such as HCQS 200 and HCQS 400, initially seemed promising in combating COVID-19. Initial speculation indicated it could decrease the viral load in those infected, possibly shortening symptom duration and lessening the chance of critical disease progression. Hydroxychloroquine's anti-inflammatory benefits were deemed useful in preventing the immune system's overreaction to the virus, often leading to complications in serious cases. This potential upside led to increased interest in HCQS as a possible therapeutic aid against the new coronavirus, spurring research and discussion within medical and scientific circles. This optimism was amplified by the urgent need for successful treatments during the pandemic's early phases, mirroring a universal wish to uncover a solution in the midst of ambiguity.